Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: Biologic insights and clinical opportunities

Journal of Oral Pathology and Medicine

Volumn 34, Issue 8, 2005, Pages 449-459

  Wreesmann, V B ^a   Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diagnosis; Genetics; Head and neck neoplasms; Prognosis; Treatment

Indexed keywords

BEVACIZUMAB; CELECOXIB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; LONAFARNIB; METHOTREXATE; PERIFOSINE; RECOMBINANT DNA;

BIOINFORMATICS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RECURRENCE; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL TRIAL; GENE THERAPY; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC DAMAGE; GENETIC HETEROGENEITY; GENETIC IDENTIFICATION; HEAD AND NECK CARCINOMA; HUMAN; KARYOTYPING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; GENE TARGETING; GENE THERAPY; GENETIC HETEROGENEITY; GENETIC SCREENING; HEAD AND NECK NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; PROGNOSIS;

EID: 23844481813     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2005.00343.x     Document Type: Review

References (125)

1. Sutton WS. The chromosomes in heredity. Biol Bull 1903; 231-51.
2. Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, et al. The molecular basis of alkaptonuria. Nat Genet 1996; 14: 19-24.
3. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res 2000; 462: 247-53.
4. Bhattacharyya MK, Smith AM, Ellis TH, Hedley C, Martin C. The wrinkled-seed character of pea described by Mendel is caused by a transposon-like insertion in a gene encoding starch-branching enzyme. Cell 1990; 60: 115-22.
5. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
6. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003; 33(Suppl): 238-44.
7. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003; 34: 369-76.
8. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-603.
9. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-6.
10. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
11. Prime SS, Thakker NS, Pring M, Guest PG, Paterson IC. A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol 2001; 37: 1-16.
12. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-9.
13. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998; 95: 13692-7.
14. Stoler DL, Chen N, Basik M, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 1999; 96: 15121-6.
15. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7.
16. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 1999; 9: M57-60.
17. Jallepalli PV, Waizenegger IC, Bunz F, et al. Securin is required for chromosomal stability in human cells. Cell 2001; 105: 445-57.
18. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003; 3: 695-701.
19. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300-3.
20. Rajagopalan H, Jallepalli PV, Rago C, et al. Inactivation of HCDC4 can cause chromosomal instability. Nature 2004; 428: 77-81.
21. Wang Z, Cummins JM, Shen D, et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 2004; 64: 2998-3001.
22. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res 2003; 63: 6212-20.
23. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
24. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304: 1164-6.
25. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
26. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
27. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
28. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining (Letter). Nature 1973; 243: 290-3.
29. Heisterkamp N, Groffen J. Molecular insights into the Philadelphia translocation. Hematol Pathol 1991; 5: 1-10.
30. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 33-44.
31. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-64.
32. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557-63.
33. Kroll TG, Sarraf P, Peccianni L, et al. PAX8-PPAR-gamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289: 1357-60.
34. Wreesmann VB, Ghossein RA, Hezel M, et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 2004; 40: 355-64.
35. Mitelman F, Johansson B, Mandahl N, Mertens F. Clinical significance of cytogenetic findings in solid tumors. Cancer Genet Cytogenet 1997; 95: 1-8.
36. Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis 2000; 21: 443-52.
37. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 2002; 161: 1549-56.
38. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 2004; 64: 871-5.
39. Thiagalingam S, Laken S, Willson JK, et al. Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc Natl Acad Sci U S A 2001; 98: 2698-702.
40. Devilee P, Cleton-Jansen AM, Cornelisse CJ. Ever since Knudson. Trends Genet 2001; 17: 569-73.
41. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-21.
42. Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996; 273: 494-7.
43. Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 1998; 58: 4260-3.
44. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
45. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Anti-proliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7: 961-6.
46. Monni O, Hyman E, Mousses S, Barlund M, Kallioniemi A, Kallioniemi OP. From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Semin Cancer Biol 2001; 11: 395-401.
47. Wang TL, Maierhofer C, Speicher MR, et al. Digital karyotyping. Proc Natl Acad Sci U S A 2002; 99: 16156-61.
48. Barlund M, Forozan F, Kononen J, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000; 92: 1252-9.
49. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004; 64: 3780-9.
50. Slonim DK. From patterns to pathways: gene expression data analysis comes of age. Nat Genet 2002; 32(Suppl.): 502-8.
51. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890-900.
52. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129: 106-12.
53. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-56.
54. Kutler DI, Wreesmann VB, Goberdhan A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2003; 95: 1718-21.
55. Hoglund M, Jin C, Gisselsson D, Hansen GB, Mitelman F, Mertens F. Statistical analyses of karyotypic complexity in head and neck squamous cell carcinoma. Cancer Genet Cytogenet 2004; 150: 1-8.
56. Singh B, Gogineni SK, Sacks PG, et al. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res 2001; 61: 4506-13.
57. Wreesmann VB, Shi W, Thaler H, et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22: 3965-72.
58. Bockmuhl U, Schluns K, Kuchler I, Petersen S, Petersen I. Genetic imbalances with impact on survival in head and neck cancer patients. Am J Pathol 2000; 157: 369-75.
59. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM, Sidransky D. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994; 54: 1152-5.
60. Ah-See KW, Cooke TG, Pickford IR, Soutar D, Balmain A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res 1994; 54: 1617-21.
61. Squire JA, Bayani J, Luk C, et al. Molecular cytogenetic analysis of head and neck squamous cell carcinoma: by comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 2002; 24: 874-87.
62. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54: 1156-8.
63. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-92.
64. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
65. Weber RG, Scheer M, Born IA, et al. Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. Am J Pathol 1998; 153: 295-303.
66. Ha PK, Benoit NE, Yochem R, et al. A transcriptional progression model for head and neck cancer. Clin Cancer Res 2003; 9: 3058-64.
67. Bockmuhl U, Petersen I. DNA ploidy and chromosomal alterations in head and neck squamous cell carcinoma. Virchows Arch 2002; 441: 541-50.
68. Zhang L, Rosin MP. Loss of heterozygosity: a potential tool in management of oral premalignant lesions? J Oral Pathol Med 2001; 30: 513-20.
69. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2: 682-5.
70. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712-7.
71. Califano J, Westra WH, Koch W, et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 1999; 91: 599-604.
72. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-7.
73. Boyle JO, Mao L, Brennan JA, et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 1994; 168: 429-32.
74. Huang Q, Yu GP, McCormick SA, et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer 2002; 34: 224-33.
75. Bardelli A, Cahill DP, Lederer G, et al. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A 2001; 98: 5770-5.
76. Singh B, Wreesmann VB, Pfister D, et al. Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure. BMC Genet 2002; 3: 22.
77. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004; 96: 998-1006.
78. Dahlgren L, Mellin H, Wangsa D, et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003; 107: 244-9.
79. Sy SM, Wong N, Mok TS, et al. Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. Lung Cancer 2003; 41: 91-9.
80. Wong MP, Fung LF, Wang E, et al. Chromosomal aberrations of primary lung adenocarcinomas in non-smokers. Cancer 2003; 97: 1263-70.
81. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res 2002; 62: 3244-50.
82. Shah SI, Yip L, Greenberg B, et al. Two distinct regions of loss on chromosome arm 4q in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2000; 126: 1073-6.
83. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 1999; 109: 1544-51.
84. Partridge M, Emilion G, Langdon JD. LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. Br J Cancer 1996; 73: 366-71.
85. Coon SW, Savera AT, Zarbo RJ, et al. Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma. Int J Cancer 2004; 111: 206-12.
86. Singh B, Stoffel A, Gogineni S, et al. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol 2002; 161: 365-71.
87. Bockmuhl U, Ishwad CS, Ferrell RE, Gollin SM. Association of 8p23 deletions with poor survival in head and neck cancer. Otolaryngol Head Neck Surg 2001; 124: 451-5.
88. Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 1998; 20: 113-8.
89. Gasparotto D, Vukosavljevic T, Piccinin S, et al. Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer 1999; 84: 432-6.
90. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79: 380-9.
91. Lazar AD, Winter MR, Nogueira CP, et al. Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. Clin Cancer Res 1998; 4: 2787-93.
92. Lee DJ, Koch WM, Yoo G, et al. Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Clin Cancer Res 1997; 3: 501-5.
93. Pearlstein RP, Benninger MS, Carey TE, et al. Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 1998; 21: 333-9.
94. Reis PP, Rogatto SR, Kowalski LP, et al. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene 2002; 21: 6480-7.
95. Ashman JN, Patmore HS, Condon LT, Cawkwell L, Stafford ND, Greenman J. Prognostic value of genomic alterations in head and neck squamous cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 2003; 89: 864-9.
96. Fitzsimmons SA, Ireland H, Barr NI, et al. Human squamous cell carcinomas lose a mortality gene from chromosome 6q14.3 to q15. Oncogene 2003; 22: 1737-46.
97. Belbin TJ, Singh B, Barber I, et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 2002; 62: 1184-90.
98. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5: 489-500.
99. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004; 64: 55-63.
100. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001; 294: 1343-6.
101. Masayesva BG, Ha P, Garrett-Mayer E, et al. Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. Proc Natl Acad Sci U S A 2004; 101: 8715-20.
102. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002; 16: 984-93.
103. Redon R, Hussenet T, Bour G, et al. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res 2002; 62: 6211-7.
104. Virgilio L, Shuster M, Gollin SM, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci U S A 1996; 93: 9770-5.
105. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res 2001; 61: 4122-9.
106. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003; 25: 67-73.
107. Gollin SM. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck 2001; 23: 238-53.
108. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3.
109. Okami K, Wu L, Riggins G, et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 1998; 58: 509-11.
110. Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63: 1188-91.
111. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-85.
112. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003; 21: 4546-52.
113. Ganly I, Singh B. Topical ONYX-015 in the treatment of premalignant oral dysplasia: another role for the cold virus? J Clin Oncol 2003; 21: 4476-8.
114. Wang MB, Billings KR, Venkatesan N, Hall FL, Srivatsan ES. Inhibition of cell proliferation in head and neck squamous cell carcinoma cell lines with antisense cyclin D1. Otolaryngol Head Neck Surg 1998; 119: 593-9.
115. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999; 59: 4876-81.
116. Estilo CL, O-charoenrat P, Ngai I, et al. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res 2003; 9: 2300-6.
117. Talbot SG, O-charoenrat P, Sarkaria IS, et al. Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A. Ann Surg Oncol 2004; 11: 530-4.
118. Wang TL, Diaz LA Jr, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004; 101: 3089-94.
119. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003; 63: 8097-102.
120. Pao W, Miller VA, Kris MG. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol 2004; 14: 33-40.
121. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7.
122. Kelly K, Averbuch S. Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol 2004; 31: 93-9.
123. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
124. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
125. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.